Introduction
Melanotransferrin (MTf), also called human melanoma antigen p97, is a glycosylated protein and is part of the transferrin family (1, 2) . The transferrin family also contains serum transferrin (Tf), lactoferrin and ovotransferrin. There are two forms of endogenous MTf described to date; a membrane-bound form (mMTf), which is anchored to the cell membrane by a glycosylphosphatidylinositol-anchor, and a soluble secreted form (sMTf) (3) . Expressed only slightly in normal tissues, MTf is present in much larger amounts in neoplastic cells such as melanomas and fetal tissues (2) . Studies have shown that MTf is expressed in various tissues, such as sweat gland ducts, salivary glands, liver endothelial cell (EC), brain endothelium and chondrocytes (4) . Since MTf is an iron-binding protein that shares 39% protein sequence identity with Tf and lactoferrin (1) , it was first thought that MTf could serve as an iron transporter; however, it was later shown that MTf played very little role in iron transport (5) (6) (7) . We recently showed that both forms of MTf could bind plasminogen and stimulate its activation into plasmin by plasminogen activator (PA) (8, 9) , thus regulating cell motility, migration and invasion.
Angiogenesis, the process of new blood vessel growth from pre-existing capillaries, is involved in physiological and pathological processes such as embryonic development, wound healing, reproductive cycles, diabetic retinopathy, chronic inflammation, tumor growth and metastasis (10) . This process involves EC proliferation, migration and morphogenic differentiation into capillary-like structures (tubulogenesis) (11) . Thus, suppression of abnormal angiogenesis may provide therapeutic strategies for the treatment of angiogenesis-dependent disorders. In our laboratory, we have found that truncated sMTf could inhibit EC migration and tubulogenesis in vitro. In fact, truncated sMTf disturbs the regeneration of the free and active urokinase-type PA receptor (u-PAR) at the cell surface by the low-density lipoprotein receptor-related protein, which in turn reduces the EC capacity to generate plasmin from plasminogen (12) .
In the present study, since MTf regulates a crucial step involved in angiogenesis, we used the in vivo MatrigelÔ plug angiogenesis assay to investigate the ability of a human, truncated form of sMTf to inhibit neovascularization in mice. We show that MTf-expressing cells stimulate neovascularization of the MatrigelÔ implant, which can be inhibited by the addition, into the matrigel, of the L235 monoclonal antibody (mAb) directed against MTf. Moreover, subcutaneous (s.c.) administration of a truncated form of sMTf inhibits SK-Mel-28-as well as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) induced in vivo angiogenesis. Altogether, our results strongly suggest that MTf participates in the neovascularization of solid tumors and that s.c. administration of truncated sMTf appears to be of potential interest as an antiangiogenesis treatment modality in clinical testing.
Materials and methods

Materials
Truncated human recombinant sMTf, which is produced by introducing a stop codon following the glycine residue at position 711 of full-length MTf cDNA (producing a 27 C-terminal amino acid deletion), and the L235 mAb were kindly provided by Biomarin Pharmaceutical (Novato, CA Laboratories Limited (Hornby, ON). Other biochemical reagents were from Sigma-Aldrich (Oakville, ON).
Cell culture
Cells were cultured under 5% CO 2 /95% air atmosphere. Human umbilical vessel EC (HUVEC) were obtained from American Type Culture Collection (ATCC, Manassas, VA). HUVEC were cultured in EC basal medium-2 (EBM-2; Bullet kit, Clonetics, San Diego, CA). CHO cells (control and MTf-transfected) were cultured in Ham's F12 medium from Invitrogen (Burlington, ON) containing 10 mM HEPES and 10% calf bovine serum (Hyclone, Logan, UT). Human melanoma SK-Mel-28 cells were obtained from ATCC. SK-Mel-28 cells were grown in modified Eagle's medium from Invitrogen containing 1 mM Na pyruvate and 10% fetal bovine serum (Hyclone).
Capillary-like structure formation (tubulogenesis) assay Phenol red MatrigelÔ (50 ml; BD Bioscience, Mississauga, ON) was mixed with concentrated (16·, 10 000 MWCO) cell conditioned media (4 : 1) or truncated sMTf (20 and 200 mg/ml), added to a 96-well plate and incubated for 10 min at 37 C. HUVEC were harvested by trypsinization. A total of 2.0 · 10 4 cells were resuspended in 100 ml medium (1% serum) and added to MatrigelÔ-coated wells. After 30 min incubation at 37 C, truncated sMTf (0, 10 and 100 nM) in fresh, serum-free medium was added over the cells. Cells were then incubated for 18 h at 37 C. After incubation, tubular structures were visualized at a 50· magnification using a Nikon TMS-F microscope. The length of the total capillary network was digitized and quantified using Northern Eclipse software (Empix Imaging, Mississauga, ON).
In vivo MatrigelÔ plug angiogenesis assay
The MatrigelÔ implantation assay was based on the method of Passaniti (13) . Angiogenesis was considered to be indicated by the growth of blood vessels from s.c. tissue into a solid gel of MatrigelÔ extracellular matrix. Specific pathogen-free, female athymic Crl:CD-1 Ò -nuBR nude mice were obtained from Charles River Laboratories (Lassalle, QC). All mice used were 5-10 weeks of age. All animal studies were conducted in accordance with recommendations from the Canadian Council on Animal Care (CCAC) for care and use of experimental animals. Before injection, heparin was incubated with or without bFGF, VEGF or cells (SK-Mel-28, control and MTf-transfected CHO cells) for 5 min, then diluted into phenol red-free MatrigelÔ on ice for a final concentration of 0.0025 units/ml heparin, 250 ng/ml bFGF, 200 ng/ml VEGF and 2 · 10 6 cells/ml. Then, mice were subcutaneously injected under anesthesia in the ventral midline region of the right flank with 0.5 ml of MatrigelÔ alone or with MatrigelÔ containing bFGF, VEGF or cells. After 7 days, the mice were euthanized and the MatrigelÔ implant was harvested and washed with phosphate-buffered NaCl solution (PBS; 138 mM NaCl, 2.8 mM KCl, 1.47 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 , pH 7.4). Then, MatrigelÔ implants were photographed with a digital Nikon Coolpix TM 5000 camera (Nikon Canada, Mississauga, ON). The remaining implants were immediately frozen and lyophilized overnight. The weight of each dry MatrigelÔ implant was determined and the implants were resuspended in 0.4 ml of 0.1% Triton X-100 for 1 h, disrupted by vigorous pipetting and centrifuged at 14 000 · g for 15 min to remove particulates. The concentration of hemoglobin (Hb) in the supernatant was then determined directly by absorbance at 405 nm and compared with a standard curve of purified Hb, as described previously (14, 15) .
Procedures for testing efficacy of antiangiogenic molecules
Testing of antiangiogenic substances was initiated at the time of MatrigelÔ implantation. First, treatment with either e-amino-n-caproic acid (eACA; 35 mg/ml) as well as with mAb L235 or with non-specific, control IgG (25, 50 and 100 nM) was performed by diluting eACA or the antibodies directly in the phenol red-free MatrigelÔ before implantation. Secondly, systemic treatment with various concentrations of truncated sMTf (2.5, 5.0 and 10 mg/kg/mouse; 4 times/week; over 7 days) was performed by s.c. injection at Day 0, 2, 4 and 6 post-implantation. Thirdly, to achieve maximal long-term treatment with truncated sMTf, an Alzet Ò (Cupertino, CA) osmotic pump (100 ml, 7-day delivery) was implanted subcutaneously in the dorsal infrascapular region to deliver various concentrations of truncated sMTf ( 6 CPM). At the allotted times, blood samples (50 ml) were withdrawn from the tail vein into a heparinized Microvette Ò CB 300 (Sarstedt, Nümbecht, GE) container. The concentration of truncated sMTf was then quantified by measuring blood-associated radioactivity using a gamma counter.
Data statistical analysis
Statistical analyses were made with Student's t-test when one group was compared with the control group. To compare two or more groups with each others, one-way analysis of variance (ANOVA) and Tukey's multiple comparison test as post-test were used. All statistical analyses were made using GraphPad Prism (San Diego, USA). Significance was assumed for P-values < 0.05.
Results
Truncated sMTf inhibits HUVEC tubulogenesis
In the present study, since MTf expression stimulates cell motility, migration and invasion (9) , the in vitro morphogenic differentiation of EC into capillary-like structures (tubulogenesis) on MatrigelÔ was examined under several conditions. Hence, we first examine the effects of MatrigelÔ-trapped MTf-expressing cell conditioned media on HUVEC tubulogenesis ( Figure 1A ). MTf is highly expressed by both MTftransfected CHO and SK-MeL-28 cells, whereas control CHO and HUVEC cells do not express detectable levels of MTf (8, 9, 12) . Moreover, the expression levels of secreted endogenous sMTf in MTf-transfected CHO and SK-Mel-28 cells is much lower than their mMTf expression. HUVEC cell growth on Matrigel produced a stabilized network of capillary-like structures. The tubulogenesis of HUVEC cells was stimulated $2-fold by the addition of conditioned media from MTf-transfected cells and SK-Mel-28 cells nor control cells into the MatrigelÔ ( Figure 1A ). We also determined the effects of exogenous truncated sMTf on this phenomenon. Interestingly, the addition in the medium of truncated sMTf (10-100 nM) during the assay inhibits both basal and MTfinduced tubulogenesis of HUVEC cells in a concentrationdependent manner ( Figure 1A ), without affecting cell proliferation (data not shown). Moreover, to determine whether the increase in HUVEC tubulogenesis, induced by the addition of conditioned medium from MTf-expressing cells, could be related to the presence of matrix-bound sMTf, truncated sMTf was added (1 and 10 mg) into the matrigel ( Figure 1B ). MatrigelÔ-trapped truncated sMTf induced the tubulogenesis of HUVEC in a concentration-dependent manner. Altogether, these results indicate that matrix-bound sMTf could induce capillary-like tube formation of EC and that truncated sMTf antagonized this effect.
bFGF-induced neovascularization involves the PA/plasmin system We used the MatrigelÔ plug neovascularization assay to study the effect of MTf on the modulation of in vivo angiogenesis. This assay permits the determination of the extent of angiogenesis into the MatrigelÔ implant by direct measurement of the amount of Hb present in the implant. Analysis of the MatrigelÔ implants that did not contain growth factor showed very low pink hue coloration (Hb content), indicating that MatrigelÔ itself was not angiogenic (Figure 2 ; upper panel). In contrast to MatrigelÔ control condition, MatrigelÔ implants containing bFGF showed strong neovascularization ( Figure 2 ; upper panel). In the presence of bFGF alone, the amount of Hb was increased by 3-fold over the level found in control plugs containing no added growth factor ( Figure 2 ; lower panel). The implication of the PA/plasmin system during the in vivo MatrigelÔ plug neovascularization induced by bFGF was determined by adding into the implant the plasmin(ogen) inhibitor eACA during the assay. Lysine derivatives, such as eACA, are effective inhibitors of the PA/plasmin system (9, 16, 17) . The addition of eACA (35 mg/ml) into the plug strongly inhibited by $80% the angiogenic response elicited by bFGF, as indicated by the lower implant vascularization (Figure 2 ; upper panel) and lower Hb content (Figure 2 ; lower panel). These results suggest that plasmin generation from plasminogen is involved during bFGF-induced in vivo angiogenesis, indicating that this model is suitable for studying the impact of MTf on in vivo angiogenesis since MTf modulates plasmin generation by PA from plasminogen.
Subcutaneous, systemic truncated sMTf treatments inhibit bFGF-and VEGF-induced neovascularization Given the important role of plasmin (18), a protein like MTf that targets the formation of plasmin and acts on the invasiveness capacity of EC and SK-Mel-28 cells as well as on EC tubulogenesis might be expected to affect in vivo angiogenesis. To test this hypothesis, MatrigelÔ implant neovascularization was stimulated by bFGF and nude mice were treated systemically four times (Days 0, 2, 4 and 6 postimplantation; s.c. injection) with either truncated sMTf (10, 20 and 40 mg/kg; total treatment) or control R/H ( Figure 3A and B). In the presence of bFGF alone, there was a robust angiogenic response as indicated by the strong pink hue distributed throughout the plug ( Figure 3A) . To obtain a more quantitative analysis, the Hb content within each plug was measured to assess the angiogenic index ( Figure 3B ). When mice were treated with 10 mg/kg truncated sMTf, the amount of vascular development was reduced, whereas at 40 mg/kg the inhibition of vascularization was maximal, with a median effective dose (ED 50 ) at 14 mg/kg ( Figure 3A and B). Furthermore, to show the generality of the truncated sMTf-mediated angiogenesis inhibition, we characterized the effect of truncated sMTf s.c treatment on in vivo MatrigelÔ plug assay in the presence of another standard proangiogenic cytokine, for example, VEGF ( Figure 3C ). In contrast to MatrigelÔ control condition, MatrigelÔ implants containing VEGF showed strong neovascularization ( Figure 3C; upper panel) . In fact, the amount of Hb was increased by 3.5-fold in the presence of VEGF alone compared with control implants containing no added growth factor ( Figure 3C ; lower panel). When mice were treated systemically four times (Days 0, 2, 4 and 6 post-implantation; s.c. injection) with truncated sMTf (20 mg/kg; total treatment), the amount of vascular development within the MatrigelÔ implant was significantly reduced by 68% ( Figure 3C ; lower panel). These results indicate that truncated sMTf inhibits both bFGF-and VEGF-induced angiogenesis, suggesting that s.c. administration of truncated sMTf may provide a novel therapeutic strategy for the treatment of angiogenesis-related disorders.
MTf-expressing cells stimulate neovascularization, involvement of the PA/plasmin system Since MTf overexpression stimulates cell motility, migration and invasion (9) and MTf-expressing cell conditioned media stimulate in vitro HUVEC tubulogenesis, we determine the effects of endogenous MTf protein expression on in vivo angiogenesis. Thus, we examined the impact of CHO (control and MTf-transfected) and SK-Mel-28 melanoma cells within the implant on in vivo angiogenesis using the MatrigelÔ plug neovascularization assay ( Figure 4A ). Quantitative analysis of angiogenesis indicated that MTf-expressing cells (MTf-transfected CHO and SK-Mel-28) induced by $6-fold the neovascularization of the MatrigelÔ implants, as demonstrated by the higher Hb content, whereas CHO control cell had no significant impact on MatrigelÔ Hb content ( Figure 4A ; lower panel). In addition, MTf expression in CHO and SK-Mel-28 cells was unchanged following bFGF treatment. Also, bFGF secretion in CHO cells was unaffected by MTf transfection (data not shown). These results show that MTf expression in CHO and SK-Mel-28 cells could contribute to the increased angiogenic response in the in vivo MatrigelÔ plug neovascularization assay. Moreover, we also determined the effect of eACA into the implant on the neovascularization induced by SK-Mel-28 cells ( Figure 4B ). The presence of eACA (35 mg/ml) into the plug strongly inhibited by $75% the angiogenic response elicited by SK-Mel-28 cells, as indicated by the lower implant vascularization ( Figure 4B ; upper panel) and lower Hb content ( Figure 4B ; lower panel). These results indicate that the PA/plasmin system is involved during SK-Mel-28-induced in vivo angiogenesis.
L235 inhibits SK-Mel-28-induced neovascularization
We have previously shown that the mAb L235, which recognizes a conformational epitope on MTf, inhibits the binding of plasminogen on MTf-expressing cell, leading to the reduction of plasminogen activation into plasmin at their cell surface (8, 9) . The reduced capacity of these cells to generate plasmin from plasminogen in the presence of this mAb also leads to the inhibition of cell motility, migration and invasion (9) . The mAb L235 was used to determine whether cell-induced MatrigelÔ implant in vivo neovascularization was directly dependent on plasminogen activation induced by the MTf expression in SK-Mel-28 tumor cell. Thus, we added various concentrations of mAb L235 into the MatrigelÔ implants containing SK-Mel-28 cells ( Figure 5A and B) . The addition of L235 mAb into the MatrigelÔ inhibited, in a concentration-dependent manner, the SK-Mel-28-induced neovascularization and reached a maximal angiogenesis inhibition of 70% at 100 nM. The ED 50 calculated for the inhibition of angiogenesis by L235 is $46 nM ( Figure 5B ). Because the mAb L235 does not cross-react with other species than human, this mAb only binds to MTf expressed by the SK-Mel-28 melanoma cells. Since L235 reduces MTf-induced plasminogen activation at the cell surface and specifically inhibits SK-Mel-28-induced in vivo neovascularization of the MatrigelÔ implants, these results confirmed that MTf overexpression in these melanoma cells leads to an increased angiogenic response involving the PA/plasmin system.
Subcutaneous, systemic truncated sMTf treatments inhibit SK-Mel-28-induced neovascularization
To antagonize the proangiogenic effects linked to MTf overexpression, as observed in the presence of SK-Mel-28 cells, we used a truncated soluble form of MTf (sMTf) to inhibit MTf-induced MatrigelÔ implant neovascularization ( Figure 6 ). First, mice were treated systemically four times (Days 0, 2, 4 and 6 post-implantation; s.c. injection) with either truncated sMTf (10, 20 and 40 mg/kg; total treatment) or with control R/H ( Figure 6A ). In a second set of experiments, Alzet Ò osmotic pumps (100 ml, 7-day delivery) containing either truncated sMTf (10 and 20 mg/kg; total treatment) or control R/H were implanted subcutaneously on the same day as MatrigelÔ plugs were implanted ( Figure 6B ). Quantitative analysis of angiogenesis indicated that s.c. systemic treatment with truncated sMTf antagonized neovascularization of the MatrigelÔ implants, as demonstrated by a lower Hb content ( Figure 6C ). Moreover, continuous s.c. infusion of truncated sMTf using an Alzet Ò osmotic pump increased this antiangiogenic activity. In fact, the ED 50 was reduced from 17 mg/kg (repeated s.c. injections) to 11 mg/kg when a continuous s.c. infusion was employed. These results show the efficacy of truncated sMTf in relatively low amounts as an inhibitor of the in vivo SK-Mel-28-stimulated angiogenesis.
Pharmacokinetic characteristics of truncated sMTf in mice
To assess the pharmacokinetic characteristics of truncated sMTf in mice, blood drug levels was studied in female athymic Crl:CD-1 Ò -nuBR nude mice. The mean blood concentrations of truncated sMTf after a single 5 mg/kg s.c. injection or a continuous 20 mg/kg s.c. infusion using a Alzet Ò osmotic pump were measured ( Figure 7) . The pharmacokinetic parameters derived from these data are summarized in Table I . After a single s.c. injection, truncated sMTf appeared rapidly in the circulation attaining a concentration maximum (C max ) of 41.0 ± 8.7 nM at 3 h. Next, using an Alzet Ò osmotic pump, truncated sMTf appeared more slowly in the circulation compared with the single s.c. injection and gained a C max of 7.3 ± 1.9 nM at 144 h (Day 6). The terminal pharmacokinetics of truncated sMTf after a single s.c. administration were characterized by a slow elimination phase with a final steady state concentration (C last ) of 4.0 ± 1.5 nM, compared with 6.1 ± 1.6 nM when truncated sMTf is subcutaneously infused using an Alzet Ò osmotic pump. Also, the terminal half-life (t 1/2 ) of truncated sMTf was $7.6 ± 0.9 h. The high exposure of the vasculature to truncated sMTf was also reflected by the high area under the curve from 0.02 h to infinity (AUC 0.02À1 ) of 476.1 ± 67.7 nM·h for a single injection and 928.0 ± 59.8 nM·h for an Alzet Ò osmotic pump infusion. In addition, the truncated sMTf quantity delivered by an Alzet Ò osmotic pump infusion represents $3.5-fold the quantity of truncated sMTf delivered by a single s.c. injection. Thus, these results demonstrate that over a 7-day period treatment, the AUC 0.02À1 obtained with Ò osmotic pump, as described in the Materials and methods section. At the allotted times, blood was collected and the concentration of the compound was quantified by measuring blood-associated radioactivity using a gamma counter. Results were corrected for background radioactivity measured in untreated mice and expressed as truncated sMTf in blood (nM). The pharmacokinetic parameters derived from these data are summarized in Table I . For each conditions, n ¼ 3 and the means ± SE are shown. Ò osmotic pump conditions and the means ± SE are shown. Statistically significant differences compared with R/H control condition are indicated as follows: Ã P < 0.05; ÃÃ P < 0.01; ÃÃÃ P < 0.001 (Student's t-test). Areas under the curve from 0.02 h to infinity (AUC 0.02À1 ) were calculated using mean values. C max (maximum concentration), t max (time to maximum concentration) and C last (steady-sate concentration) were determined by inspection of the data using GraphPad Prism. Data are expressed as mean ± SE (n ¼ 3).
an Alzet Ò osmotic pump (928.0 nM·h) infusion is $51% of that observed during a single s.c. injection (1808.8 nM·h). Furthermore, after a single s.c. dosing with 2.5 and 10 mg/kg of truncated sMTf, a dose-proportional relationship was observed in blood (data not shown). Overall, these results show that s.c. dosing of truncated sMTf can achieve blood concentrations that are in the same order as those required for the inhibition of in vitro HUVEC tubulogenesis.
Discussion
Many identified antiangiogenic molecules have the potential of becoming powerful weapons in the treatment of different diseases characterized or caused by excessive angiogenesis, such as cancer, psoriasis, arthritis, blindness, obesity, asthma, arthrosclerosis and infectious disease (10) . In this study, we have demonstrated for the first time that truncated sMTf inhibits in vivo angiogenesis and this can be achieved by s.c. dosing. This follows our previous work in which we demonstrated that this form of truncated sMTf potently inhibits angiogenesis-related mechanisms using in vitro models (8, 9, 12) .
Recently, we show that MTf is a cell surface receptor for plasminogen that stimulates plasmin generation by PA (9) . Since plasminogen activation is crucial during angiogenesis, cell conditioned media were tested for their capability to induce angiogenesis in an in vitro MatrigelÔ tubulogenesis assay. Under our conditions, MTf-expressing cell conditioned media, trapped in extracellular MatrigelÔ matrix, induced HUVEC tubulogenesis. Moreover, truncated sMTf trapped in MatrigelÔ matrix also induced tubulogenesis of HUVEC. The present result is in agreement with another study from Sala et al. (19) that used the chick embryo CAM assay to show that gelatin-trapped sMTf could induce angiogenesis and that sMTf has the capacity to induce HMEC-1 cell chemotactic migration. However, in our assay, the addition of truncated sMTf antagonized basal EC tubulogenesis as well as the EC tubulogenesis induced by conditioned media from MTf-expressing cells, indicating that truncated sMTf has potent antiangiogenesis activity in vitro.
To evaluate angiogenesis in vivo and to probe the potential use of a truncated sMTf as an antiangiogenic therapeutic, we have utilized the MatrigelÔ plug neovascularization mouse model (13) . It has been noted that, in melanoma, several angiogenic cytokines are expressed, including bFGF, VEGF, IL-8 and GM-CFS, which mediates autocrine and paracrine control of melanomas (20) . Moreover, both bFGF and VEGF strongly and rapidly stimulate the induction of the PA/ plasmin system in ECs from the microvasculature (21) . The absence of tumor cells in the model using growth factors suggests that truncated sMTf could have direct antiangiogenic activity on ECs. Since truncated sMTf decreases EC cell surface plasminogen activation by affecting the expression of receptors involved in plasmin generation at the cell surface (12) , truncated sMTf could thus interfere with the PA/plasmin system that is upregulated by these angiogenic factors.
Proangiogenic effects of MTf are mediated by stimulation of cell surface plasminogen activation (8, 9) . Previous studies showed that the L235 mAb inhibits MTf-expressing cell invasiveness capacity by reducing MTf-induced plasminogen binding and activation into plasmin at their cell surface (22) . Using the L235 antibody and eACA, the in vivo proangiogenic response elicited by SK-Mel-28 was specifically related to MTf expression and involved the PA/plasmin system. Therefore, as was seen in the case of melanoma cells, MTf overexpression within the extracellular matrix could stimulate angiogenesis within the cell's microenvironment by stimulating the PA/plasmin system. Although caution is necessary when extrapolating in vitro data to explain in vivo findings, previous in vitro investigations have suggested that truncated sMTf could antagonize MTf-stimulated angiogenesis-related processes (8, 9, 12) . Various recent therapeutic approaches have aimed at the suppression of neovascularization and cancer cell growth by the use of soluble proangiogenic receptors. For example, the soluble FGF receptor (sFGFR), lacking transmembrane and cytoplasmic domains, inhibits vascularization and cancer growth by a dominant negative effect on cellular signaling and function (23, 24) . Also, the soluble platelet-derived growth factor-b receptor has the ability to interfere with PDGF signaling and PDGF-induced cell proliferation (25) . Moreover, the soluble VEGF receptor is an antiangiogenesis-dependent tumor antagonist (26) , whereas soluble u-PAR antagonizes cancer progression by inhibition of angiogenesis (27) . In our experiments, the addition of the truncated analog sMTf prevented MTf-induced cell migration, motility, invasion, tubulogenesis and in vivo angiogenesis, suggesting that truncated sMTf could decrease plasminogen activation at the cell surface of EC and/or tumor cell by a competitive mechanism. In fact, the exogenous sMTf could antagonize the proangiogenic effect of MTf-expressing cell by breaking the equilibrium between mMTf and endogenous sMTf, which in turn reduces the plasminogen activation at the cell surface. Thus, limiting the proangiogenic activity of MTf by truncated sMTf may provide a method for decreasing the vascularization of tumors and therefore limiting tumor progression or growth. Nevertheless, we cannot exclude the possibility that truncated sMTf could also modulate other mechanisms involved during angiogenesis, such as the recruitment of inflammatory cells. Altogether, these observations indicate that a truncated sMTf could be used as an antiangiogenesis biological therapy.
In addition, systemic s.c. treatment with low amounts of truncated sMTf inhibited SK-Mel-28-as well as bFGF-and VEGF-induced neovascularization. The ED 50 values for truncated sMTf are lower compared with other antiangiogenic molecules. In fact, the angiogenesis inhibitor ZD6474, an agent that selectively targets VEGFR-2 and epidermal growth factor receptor (EGFR) tyrosine kinase activity, significantly inhibited gastric tumor growth and dissemination at 100 mg/kg/day (28) , whereas the farnesyltransferase inhibitor ABT-100 showed significant reduction in tumor vascularity between 6.25 and 50 mg/kg/day (29) . Our study provides further evidences that the antiangiogenic activity of truncated sMTf demonstrates significant potential clinical application.
Furthermore, in vivo antiangiogenic efficacy data correlate with the capacity of truncated sMTf to attain blood levels that are (i) in excess of in vitro concentration values needed for the inhibition of HUVEC tubulogenesis; (ii) sufficient to almost totally block the MTf-induced HUVEC tubulogenesis; (iii) in excess of in vivo sMTf concentration measured in human serum; and (iv) sufficient to demonstrate antiangiogenic effects in a bFGF-, VEGF-and cell-driven MatrigelÔ implant neovascularization model. Also, the use of Alzet Ò osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated s.c. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects. Our results are also consistent with data on angiostatin dosing patterns in mice, where continuous infusion of the drug had a dramatically improved antiangiogenic effect over twice-daily administration of the same dose (30) . Moreover, the final steady state concentration of truncated sMTf is greater than the concentration of endogenous sMTf present in human serum (0.017-0.046 nM) (2, (31) (32) (33) , indicating that serum truncated sMTf modulation could be easily achieved. On the basis of this favorable preclinical profile, truncated sMTf appears to be of potential interest as an antiangiogenesis treatment modality in clinical testing.
In conclusion, our in vitro and in vivo data demonstrate a proangiogenic activity associated with human MTf overexpression, supporting the hypothesis that MTf may contribute to angiogenesis during melanoma progression. This MTfinduced in vivo angiogenesis is inhibited by systemic s.c. treatment with truncated sMTf, strongly indicating that truncated sMTf could be considered as a potential antiangiogenic agent.
